QC
INMB icon

Quadrature Capital’s INmune Bio INMB Stock Holding History

Quadrature Capital’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.6K Buy
32,362
+15,401
+91% +$21.9K ﹤0.01% 1295
2025
Q4 		$26.5K Buy
+16,961
New +$30.3K ﹤0.01% 1201
2025
Q2 		– Sell
-12,301
Closed -$95.8K – 1250
2025
Q1 		$95.8K Buy
+12,301
New +$97.7K ﹤0.01% 936

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Quadrature Capital's INMB Position: Q1 2026 in Review

Quadrature Capital increased its INmune Bio (INMB) stake by 91% in Q1 2026, buying an estimated $21.9K and bringing the position to 32,362 shares worth $36.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1295.

Quadrature Capital first reported a position in INMB in Q1 2025 and has held it in 3 quarters since. The position peaked at $95.8K in Q1 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • Quadrature Capital held 32,362 shares of INmune Bio worth $36.6K as of Q1 2026.
  • Quadrature Capital bought 15,401 INmune Bio shares in Q1 2026, an estimated $21.9K.
  • INmune Bio made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #1295 holding.
  • Quadrature Capital first reported a position in INmune Bio in Q1 2025 and has held it in 3 quarters since.
  • Quadrature Capital's INmune Bio position peaked at $95.8K in Q1 2025.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.